
Bioventus Inc. Class A Common Stock
NASDAQ:BVSLive AI agent
Bioventus is a global leader of innovations for active healing, established in 2012 and headquartered in Durham, NC.
Investor website: https://bioventus.com/
About
Bioventus is a global leader of innovations for active healing, established in 2012 and headquartered in Durham, NC. The company focuses on developing clinically effective, cost-efficient, minimally invasive medical treatments that enhance the body’s natural healing processes. With over 1,200 employees worldwide, Bioventus aims to partner with the healthcare community to deliver innovative medical devices that allow patients to resume active lives.
Verified company data
- Cash position
- $42,164
- Shares outstanding
- 66,973,692
- Fully diluted shares
- 68,837,797
- Leadership
- Robert Claypoole (Chief Executive Officer), Mark Singleton (Senior Vice President and Chief Financial Officer), Katrina Church (Chief Compliance Officer), Anthony D’Adamio (Senior Vice President and General Counsel), Helen Leupold (Senior Vice President, Chief Human Resources Officer), Mike Crowe (Senior Vice President, Operations), Anthony Doyle (SVP, General Manager, Pain Treatment & Restorative Therapies), Megan Rosengarten (SVP, General Manager, Peripheral Nerve Stimulation), Dave Venner (SVP, General Manager, Surgical), Jeff Ciardi (Vice President of Strategic Accounts and Market Access), Jane Fitzpatrick (Vice President of Medical Affairs), Kellie Stefaniak (Vice President of Global Regulatory and Quality), Sharath Bhat (Vice President/General Manager, EMEA APAC)
Verified data last updated:
Recent filings
- Current report pursuant to Section 13 or 15(d) · bvs_2026-08-05_10-40-11.pdf
- Statement of acquisition of beneficial ownership by individuals · bvs_2026-07-27_19-25-25.pdf
- Statement of changes in beneficial ownership of securities · bvs_2026-06-04_20-06-35.pdf
- Statement of changes in beneficial ownership of securities · bvs_2026-06-04_19-48-01.pdf
- Statement of changes in beneficial ownership of securities · bvs_2026-06-04_19-47-48.pdf
- Statement of changes in beneficial ownership of securities · bvs_2026-06-04_19-47-35.pdf
- Statement of changes in beneficial ownership of securities · bvs_2026-06-04_19-47-18.pdf
- Statement of changes in beneficial ownership of securities · bvs_2026-06-04_19-47-04.pdf